Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MannKind grants Tolero Pharmaceuticals rights to its BTK program for cancer and inflammation

Executive Summary

MannKind Corp. (therapeutics for diabetes and cancer) has granted start-up Tolero Pharmaceuticals Inc. (drug discovery based on genetic pathway abnormalities) exclusive worldwide rights to its Bruton’s tyrosine kinase (BTK) program, which is in preclinical studies for blood cancers and inflammatory diseases.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal